Introduction {#s1}
============

Neonatal diabetes mellitus (NDM) is a rare monogenic form of non-autoimmune diabetes which affects 1 in ∼300,000 live births and is diagnosed before six months of age [@pone.0013630-Vaxillaire1], [@pone.0013630-AguilarBryan1], [@pone.0013630-Murphy1]. Approximately half of the NDM cases are transient (TNDM) but can ultimately relapse. In contrast, permanent NDM (PNDM) cases need continual treatment from diagnosis [@pone.0013630-Vaxillaire1], [@pone.0013630-AguilarBryan1], [@pone.0013630-Murphy1]. More than half of both forms of NDM cases have been elucidated, so far, and it appears that the genetic aetiologies of NDM are quite heterogeneous. Indeed, although the majority of TNDM cases have an abnormality in chromosome 6q24 and the other most frequent causes of NDM are missense mutations in the pancreatic β-cell K~ATP~ channel genes *KCNJ11* and *ABCC8*, and in the preproinsulin gene, NDM has been linked to numerous other genetic causes including point mutations in *GCK*, *GLIS3*, *EIF2AK3*, *PDX1*, *PTF1A*, *SLC2A2, HNF1B* or *FOXP3* [@pone.0013630-Vaxillaire1], [@pone.0013630-AguilarBryan1], [@pone.0013630-Murphy1].

Even if the presence of specific clinical features (*e.g.* relatively late age of onset, pancreas agenesis, developmental delay, renal failure, anaemia, thyroid disease, cardiac disorders...) or a family history of diabetes or consanguinity may suggest potential molecular aetiology(ies) for NDM, a molecular genetic diagnosis is crucial as it can predict the most appropriate treatment and genuinely improve quality of life [@pone.0013630-Murphy1]. The most striking example is seen for NDM patients with a mutation in the K~ATP~ channel genes, who can be treated effectively with oral sulfonylureas that directly bind the SUR1 regulatory subunit of the channel, rather than requiring life-long insulin therapy which usually provides poor glycemic contol [@pone.0013630-Babenko1], [@pone.0013630-Pearson1], [@pone.0013630-Gloyn1].

Most developed countries offer DNA testing for NDM patients to establish a personal molecular genetic diagnosis for family counselling and to plan personalized pharmacotherapy. When severe hyperglycaemia is detected in a neonate, it is difficult to predict whether NDM will be transient or permanent. If the young patient does not have extrapancreatic features or a family history of diabetes (especially in a consanguineous context), it is suggested to first search for a chromosome 6q24 abnormality or for a *KCNJ11* mutation, as these NDM aetiologies are the most frequent, and then for mutations in *ABCC8* and *INS* if the first tests are negative [@pone.0013630-Vaxillaire1], [@pone.0013630-Murphy1]. As *KCNJ11*, *ABCC8* and *INS* altogether represent 42 coding exons, sequencing these genes using the standard Sanger protocol is obviously tedious, long and costly. If this first set of gene sequencing is negative, further molecular analysis of the other NDM genes is generally not performed. This current approach to molecular diagnosis of NDM provides only a limited sequencing of the known NDM genes and no assessment of possible modifier genetic loci elsewhere in the genome: a more comprehensive cost efficient methodology to scrutinize every new NDM case is necessary.

In the present study, we demonstrate the feasibility of next-generation whole exome sequencing (WES) for the molecular diagnosis of a patient with NDM without any extrapancreatic features or family history of diabetes. Despite previous negative Sanger sequencing of *ABCC8* by a hospital laboratory, we identified a novel non-synonymous mutation in this gene through WES. We show that this cutting-edge novel technology is more comprehensive, less labour intensive and thus cheaper for NDM diagnosis than standard sequencing protocols.

Results {#s2}
=======

The patient\'s clinical record reported that he has developed severe hyperglycemia, ketoacidosis and weight loss at two months of age. HLA typing showed neutral alleles for type 1 diabetes mellitus susceptibility. Pancreas ultrasound scan was normal and the patient did not show any specific extra-pancreatic clinical features. He was firstly treated with continuous subcutaneous insulin infusion during two years with rather low dose of insulin (\<0.5 units/kg/day) for a pretty good metabolic control (A1C \<8.5%). He was then switched with a basal-bolus scheme for technical adverse outcome. The patient is currently 20 years old. He is treated with 1.1 units/kg/day of insulin, with A1C values ranging between 8 and 9%. He always had an attention disorder and a learning disability without obvious motor symptoms or epilepsy.

After target enrichment, the whole exome DNA library from the patient was sequenced in 76 base-pairs (bp) paired-end reads, using two channels of the sequencing instrument. The WES generated 34,600,000 bp of nucleotide sequences mapping once to the targeted exome, which achieved a mean coverage of 122×of the target exome. WES identified 55,202 targeted DNA variants from the reference human genome sequence NCBI36/hg18, of which 4,463 were novel compared to the public database dbSNP130 and the eight HapMap exomes sequenced by Ng et al. [@pone.0013630-Ng1] ([Table 1](#pone-0013630-t001){ref-type="table"}). More specifically, we found 407 genes with one or more novel mutations including missense coding SNPs, gains of STOP codon and frameshift mutations ([Table 1](#pone-0013630-t001){ref-type="table"}).
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###### Number of mutations identified through the WES analysis of DNA sample from the PNDM patient.

![](pone.0013630.t001){#pone-0013630-t001-1}

  Sample                                                                                                                                  PNDM patient                                     
  ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- --------------------
  Total targetted SNPs **(Novel** [\*](#nt101){ref-type="table-fn"} **)**                                                              55,202 **(4,463)**                                  
  Homozygous SNPs                                                                                                 Total SNPs **(Novel** [\*](#nt101){ref-type="table-fn"} **)**              22,030 **(589)**
                                                                                                                        Concordance[\*](#nt101){ref-type="table-fn"} (%)                           100
                                                                                                                         Sensitivity[†](#nt102){ref-type="table-fn"} (%)                           91.8
  Heterozygous SNPs                                                                                                 Total SNPs (**Novel** [\*](#nt101){ref-type="table-fn"})                33,172 **(3,872)**
                                                                                                                         Concordance[†](#nt102){ref-type="table-fn"} (%)                           99.5
                                                                                                                         Sensitivity[‡](#nt103){ref-type="table-fn"} (%)                           95.1
  Synonymous coding SNPs                                                                                          Homozygous **(Novel** [\*](#nt101){ref-type="table-fn"} **)**               3,262 **(14)**
                                                                                                                 Heterozygous **(Novel** [\*](#nt101){ref-type="table-fn"} **)**             4,780 **(277)**
  Missense coding SNPs (a)                                                                                        Homozygous **(Novel** [\*](#nt101){ref-type="table-fn"} **)**               2,907 **(18)**
                                                                                                                 Heterozygous **(Novel** [\*](#nt101){ref-type="table-fn"} **)**             4,264 **(430)**
  Gains of STOP codon (b)                                                                                         Homozygous **(Novel** [\*](#nt101){ref-type="table-fn"} **)**                 16 **(0)**
                                                                                                                 Heterozygous **(Novel** [\*](#nt101){ref-type="table-fn"} **)**                30 **(7)**
  Insertions or deletions (c)                                                                            Homozygous **(Novel** [\*](#nt101){ref-type="table-fn"} **; Novel frameshift)**    1,748 **(951; 0)**
                                                                                                        Heterozygous **(Novel** [\*](#nt101){ref-type="table-fn"} **; Novel frameshift)**    409 **(284; 0)**
  Genes with one or more (a),(b) or (c) mutations **(Novel** [\*](#nt101){ref-type="table-fn"} **)**                                     4,495 **(407)**                                   

\**Novel*: a novel mutation means that it is not present in the public database dbSNP130 and the eight HapMap exomes sequenced by Ng et al. [@pone.0013630-Ng1].

*Concordance*: % of similar allele assignment among exomic mutations detected on the Illumina Human1M-Duo array and those discovered by WES.

*Sensitivity*: % of exomic mutations present on the Illumina Human1M-Duo array that have been discovered by WES.

To validate our WES data and analysis protocol, the patient\'s DNA was genotyped using an Illumina Human1M-Duo array, which contains 8,500 single nucleotide polymorphisms (SNPs) located in exons captured by the Agilent SureSelect technology. WES identified 7,969 exomic SNPs present on the genotyping array (93.8%), and showed high concordance rates for homozygous and heterozygous calls (100% and 99.5% and respectively). By using only one channel of the sequencing instrument, the generated sequence achieved a mean coverage of 65×of the target genome and 88.9% of the exomic SNPs present on the genotyping array were identified. These results would suggest that our WES based on the use of two channels of the genome analyzer has a low false negative rate for detecting exomic mutations, which is necessary to achieve accurate molecular diagnosis for patients presenting with monogenic disorders.

In 2004, single-stranded Sanger sequencing analysis of the patient\'s DNA by a hospital unit showed no evidence for coding mutations in *ABCC8*. Also, no abnormalities in *KCNJ11*, *INS* and chromosome 6q24 were reported by the molecular diagnostic laboratory of Robert Debré Hospital (Paris, France). Since these assessments were performed six years ago, we checked again for mutations in these three genes as well as in all other genes known to be involved in monogenic forms of diabetes. Unexpectedly, we identified a novel heterozygous non-synonymous mutation c.1455G\>C/p.Q485H in the 9^th^ exon of *ABCC8*. Based on this startling result, we used a standard Sanger sequencing protocol, to study the patient\'s DNA sample available in the CNRS-UMR8199 unit (Lille, France) as well as the sample stored at the Robert Debré hospital (Paris, France). In both cases, we identified the p.Q485H mutation in *ABCC8*, confirming our WES results. In addition, retrospective re-examination of the data generated six years ago indicated that the p.Q485H mutation was present in the original *ABCC8* exon 9 sequences (chromogram). The *ABCC8* p.Q485H mutation was not found in 348 French nondiabetic individuals or in the patient\'s mother, father and young brother, all of whom are normoglycemic. The p.Q485H mutation affects an amino acid that is located in the transmembrane domain 1 (TMD1) of the ABCC8/SUR1 core; and that is highly conserved across species (Rhesus, Mouse, Dog, Rabbit, Elephant, Opossum, Platypus, Chicken, Lizard, Stickleback, X_Tropicalis, Tetraodon) according to the UCSC (NCBI/hg18) comparative genomics alignment pipeline (<http://www.bx.psu.edu/miller_lab/>). We evaluated the possible functional significance of the p.Q485H mutation by the PolyPhen-2 (Polymorphism Phenotyping v2) software which uses sequence- and structure-based criteria to predict the putative impact of point mutations on the structure and function of human proteins [@pone.0013630-Adzhubei1]: the p.Q485H mutation is predicted 'probably damaging' with a score of 0.999 (the score of 1 indicating the most damaging mutation). Following the identification of this *ABCC8* mutation in the patient\'s DNA, a switch from insulin to oral sulfonylurea treatment will be tried soon at Necker Hospital (Paris, France).

Discussion {#s3}
==========

In the present study, we demonstrate for the first time that WES can be seen as a relevant alternative for molecular diagnosis of NDM. Since an accurate molecular diagnosis for this condition can lead to very dramatic improvements in patient care, development of reliable and cost efficient methods for quick and accurate DNA analysis are of major interest.

Currently, patients with NDM are evaluated using Sanger sequencing, which is far more expensive per sequenced base-pairs than WES. Indeed, the standard sequencing of a single PCR fragment costs 67.50€ (\$82) for the only French hospital laboratory specialized in NDM molecular diagnosis (Robert Debré hospital, Paris). This price includes consumables, equipment amortization, personnel salary and hospital overhead costs. Therefore, the total cost for the French National Insurance for the sequencing of *KCNJ11*, *ABCC8* and *INS* alone, which requires 42 PCR fragments is 2,835€ (\$3,440; ∼0.45€ or ∼\$0.55 per bp). In comparison, the all inclusive cost of WES for NDM, which will detect mutations in *KCNJ11*, *ABCC8* and *INS* as well as rarer genetic aetiologies of NDM, is currently 3,274€ (\$4,146; \<\<0.001€ or \$ per bp) per sample, by performing a sequencing on two channels and in 76 bp paired-end configuration (CNRS-UMR8199, Lille, France). Moreover, it is very likely that WES cost will fall in next months towards 2,000€ (\$2,528) or even less.

We believe that the WES protocol is less labour intensive and time-consuming than the standard Sanger protocol for genetically heterogeneous disorders requiring several large genes to be screened. A WES run involving four DNA samples can be completed in two weeks, including the time required to analyse the data, which is comparable to the time required by current Sanger sequencing of *ABCC8* only with its 39 exons. The p.Q485H mutation was missed six years ago by the research assistant in charge of the sequence reading. Although we can assume that mutation detection bio-informatics tools were less efficient a few years ago (the hospital laboratory used the PhredPhrap software in 2004) and that current methods are more accurate, the Sanger protocol and specially the semi-automated reading of sequence traces is always laborious and demanding (thus expensive), and a double-check of sequence readings by two different persons is performed in several French diagnostic laboratories in order to avoid any errors in the mutation identification process.

WES method is not only a cost-effective tool for molecular diagnosis; it should be also seen as an excellent tool for further genetic research and identification of novel causal mutations. Indeed, in the French NDM cohort, half of PNDM cases are still not elucidated [@pone.0013630-Polak1], [@pone.0013630-Vaxillaire2]. Classical linkage analyses are generally not successful as many NDM mutations occur *de novo* or are not fully penetrant. Most NDM genes have been found via candidate gene analyses but this approach has now reached its limits [@pone.0013630-Edghill1]. However, WES typically yields thousands of 'novel' genetic variants (*i.e.* not yet present in human genome variants databases). Therefore, the identification of truly causal variants would be strongly facilitated by the development of a high quality WES database of novel mutations found in both elucidated cases or in cases of unknown aetiology as well as in controls coming from same ethnicity. WES would also permit the identification of putative NDM modifier genes, a very challenging task for targeted gene analysis.

We are quite confident that the p.Q485H mutation is likely to be functional given the non ambiguous prediction of its putative damaging effect. In addition, the clinical data from the patient fit well with the features of PNDM linked to a *ABCC8* mutation (*e.g. de novo* mutation associated with very early-onset of the disease and attention disorder) [@pone.0013630-Babenko1], [@pone.0013630-Ellard1].

We believe that other NDM patients should be assessed with the same protocol as DNA quality may change the WES accuracy. Also, our DNA capture was not totally perfect as we could miss approximately 6% of exomic SNPs present in the high-resolution oligonucleotide genotyping array. Furthermore, the exomic coverage was not homogeneous between NDM genes ([Table 2](#pone-0013630-t002){ref-type="table"}), thus we could suspect that the WES accuracy would not be the same for all NDM genes. Therefore, despite high WES mean coverage and elevated rates of both concordance and sensitivity in mutation detection, it is also necessary to assess and to verify the homogeneity of the target capture, specially in the genes of interest that have to be screened for molecular diagnosis ([Table 2](#pone-0013630-t002){ref-type="table"}).
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###### Details on exomic sequencing depth in NDM genes, obtained through the WES of the PNDM patient.

![](pone.0013630.t002){#pone-0013630-t002-2}

  NDM genes    Chromosome     Start        End      Number of coding exons   Exomic size (bp)   Number of mapped 76 bp exomic reads   Mean exomic coverage   \% of sequenced exomic genes according to several depth thresholds                
  ----------- ------------ ----------- ----------- ------------------------ ------------------ ------------------------------------- ---------------------- -------------------------------------------------------------------- ------ ------ ------
  *KCNJ11*       chr11      17365042    17366214              1                    1173                         984                          57.1×                                          100                                   88.7   50.5   13.6
  *ABCC8*        chr11      17371114    17454899              39                   4746                        6235                          90.5×                                          94.6                                  85.0   54.5   31.6
  *INS*          chr11       2137658     2138777              2                    333                          97                           24.4×                                          87.1                                  65.8    0      0
  *GCK*           chr7      44164197    44159587              12                   2012                        1055                          46.1×                                          70.8                                  44.1   19.0   14.4
  *GLIS3*         chr9       3818272     4115864              9                    2328                        3672                          130.4×                                         84.8                                  79.4   67.8   39.9
  *EIF2AK3*       chr2      88638369    88707907              17                   3351                        9507                          214.1×                                         92.2                                  92.0   87.1   81.4
  *PDX1*         chr13      27392276    27396838              2                    852                          179                          27.2×                                          40.3                                  24.5   3.9     0
  *PTF1A*        chr10      23521466    23522840              2                    986                          405                          59.9×                                          38.8                                  36.4   26.3   7.0
  *SLC2A2*        chr3      172198386   172227153             11                   1575                        3669                          170.9×                                         99.6                                  99.2   88.8   69.8
  *HNF1B*        chr17      33121488    33178988              9                    1674                        2089                          94.5×                                          93.3                                  83.4   53.5   34.5
  *FOXP3*         chrX      48994739    49001906              11                   1296                         402                          25.6×                                          69.7                                  51.9   13.8    0

Knowing that the capture technology is improving day after day (by enriching exomic loci poorly captured with the previous kits), our present study suggests that it will be possible to soon update the protocols for molecular diagnosis of NDM [@pone.0013630-Murphy1], [@pone.0013630-Hattersley1]. We propose that after discovery of severe hyperglycemia in a neonate who is negative for serological markers of type 1 diabetes, a preliminary assessment of abnormalities of chromosome 6q24 can be performed (as at this stage, it is too early to guess NDM will be permanent or transient) followed by the search of a mutation in both *KCNJ11* and *INS* using Sanger sequencing as these two genes can be easily and quickly sequenced. If negative, we propose a WES analysis of the patient\'s DNA which is the most comprehensive way to fully explore the molecular causes of this NDM case.

Materials and Methods {#s4}
=====================

Study participant and DNA samples {#s4a}
---------------------------------

For WES, we selected a patient of European origin, diagnosed with PNDM who was referred to the French Network for the Study of Neonatal Diabetes Mellitus [@pone.0013630-Polak1]. He was born from non consanguineous parents and had no intra-uterine growth retardation (birth weight 2,900 g/birth length 50 cm at 40 gestational weeks). He underwent a thorough clinical examination and his medical records were reviewed. Assessment of neurological outcome was also performed. Initial diagnostic testing for mutations in *KCNJ11*, *ABCC8* and *INS*, and for chromosome 6q24 abnormalities was negative. DNA samples from the patient\'s parents and his young brother were available for genetic testing.

Ethics Statement {#s4b}
----------------

The study was approved by the local ethics committees (Assistance Publique -- Hôpitaux de Paris, ClinicalTrials.gov Identifier: NCT00610038), and both parents gave written informed consent for the genetic testing of their child.

Targeted capture and massive parallel sequencing {#s4c}
------------------------------------------------

Approximately 187,000 coding exons from 3 µg of genomic DNA from the patient were captured using the Agilent SureSelect Human All Exon kit, following the manufacturer\'s protocols. Briefly, DNA was sheared by acoustic fragmentation (Covaris) and purified using the QIAquick PCR Purification Kit (Qiagen). The quality of the fragmentation and purification was assessed with the Agilent 2100 Bioanalyzer. The fragment ends were repaired and adaptors were ligated to the fragments (NEBNext DNA sample prep, New England Biolabs). The resulting DNA library was purified using the QIAquick PCR Purification Kit, amplified by PCR and captured by hybridization to the biotinylated RNA library "baits" (Agilent). Bound genomic DNA was purified with streptavidin coated magnetic Dynal beads (Invitrogen) and re-amplified. The whole-exome DNA library was sequenced on the Illumina Genome Analyzer IIx in 76 bp paired-end reads and using two channels.

Read mapping, variant analysis and quality test of the sequencing protocol {#s4d}
--------------------------------------------------------------------------

Sequence reads were mapped to the reference human genome (UCSC NCBI36/hg18) using the ELANDv2 software (Illumina). Variant detection was performed with the CASAVA software (version 1.6, Illumina) and filtered to fit a CASAVA quality threshold ≥10 and depth of ≥8× CASAVA filters duplicate reads and reads without matched pairs.

A genomic DNA sample from the patient was genotyped on the Illumina Human 1M-Duo DNA Analysis BeadChips (with a call rate of 99.3%) as previously described [@pone.0013630-Sladek1]. We assessed the rate of exomic single nucleotide polymorphisms (SNPs) present on the array that were identified by WES and we calculated the concordance between the two methods.

Mutation validation {#s4e}
-------------------

The p.Q485H mutation identified via WES was confirmed using the Sanger method. Primer sequences and PCR conditions are available upon request to authors. The PCR fragment fitting the 9^th^ exon of *ABCC8* was sequenced using a standard protocol and the automated 3730xl DNA Analyser (Applied Biosystems). Electrophoregram reads were assembled and analysed with the Variant Reporter software (Applied Biosystems).
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